Myriad's 11% Q2 Slump Stunned Investors-Now the Real Test Begins

Why the Q2 miss hit Myriad's credibility

Myriad's latest report was a clear disappointment. The company printed Q2 revenue of $190.70 million, reported Adjusted EPS loss of $0.25, and then cut full-year guidance. Investors responded harshly: Stock price change since market close: -29.03%, with the shares at roughly $2.91 in extended trading.

That reaction matters because the guide cut made this more than a one-quarter miss. Myriad lowered its 2026 revenue outlook to $770 million to $790 million and cut full-year gross margin guidance to 66% to 67%. For now, the story looks damaged rather than merely discounted.

Myriad's revenue fell because reimbursement weakened

Volume held up better than price

On the surface, the quarter looked less bad than the 11% revenue decline suggested. Total test volume decreased 1% year over year, while average revenue per test decreased 9%, including an $11 million headwind from lower prior-period collections. That points to a reimbursement problem as much as a demand problem.

This is an important distinction. If demand is mostly intact, product momentum and sales execution can help. But if realized prices keep falling, growth initiatives become more expensive and slower to offset the shortfall.

Cancer Care Continuum still showed some underlying demand

The company's strongest operating signal came from Cancer Care Continuum. Cancer Care Continuum Revenue: $114.1 million, down 11% year over year, with test volume growth of 6% offset by a 15% decline in average revenue per test. That suggests clinicians were still ordering more tests, even as reimbursement reduced the dollars captured on each one.

Myriad also highlighted continued product motion in the segment, including the launch of Prolaris + AI for prostate cancer and the expansion of Precise MRD to include colorectal and renal cancers. Those moves matter because they show the business still has active products to support the next recovery phase.

The weak spots still matter

Not every franchise looked stable. Prenatal Health Revenue: $40 million, down 16% year over year, reflecting an 8% decline in average revenue per test and a 9% volume decline. That is a cleaner bear-case signal: both volume and pricing weakened.

GeneSight was mixed as well. Mental Health Revenue (GeneSight): $36.8 million, down 3% year over year on 4% volume growth, impacted by a $4 million write-off of aged receivables. Volume held up modestly, but the receivables write-off is another reminder that realized economics still need improvement.

What has to happen for MYGN to look investable again

Myriad now has a simpler test than usual: prove the guide cut was a reset, not the start of a deeper slide.

The company is now guided to Full-Year 2026 Revenue Guidance: Lowered to $770 million to $790 million, with Full-Year 2026 Gross Margin Guidance: Lowered to 66% to 67%. That makes the next few quarters about execution, not narrative. Investors need to see volumes stabilize, reimbursement improve, and new products contribute meaningfully.

The watch list

• Whether the submission of Precise MRD for breast cancer to MolDX for coverage determination leads to follow-through.
• Whether reimbursement initiatives expected to improve reimbursement predictability and performance start showing up in realized pricing.
• Whether gross-margin progress excluding the $11 million impact from changes in estimate, gross margin was 68.4% can become more durable.

If those items improve together, the stock can move from damaged to watchlist. If not, the market's reaction may still be too early.